Interstitial lung disease incidence and mortality in the UK and the European Union: an observational study, 2001–2017

Abstract

ObjectiveTo compare the trends in age-standardised incidence and mortality from interstitial lung diseases (ILD) in the United Kingdom (UK) and the European Union (EU).DesignObservational study using data obtained from the Global Burden of Disease Study.Setting and ParticipantsResidents of the UK and of the twenty-seven EU countries.Main outcome measuresILD age-standardised incidence rates per 100 000 (ASIR), age-standardised death rates per 100 000 (ASDR), and mortality-to-incidence ratio (MIRs) are presented for males and females separately for each country, for the years 2001–2017. Trends were analysed using Joinpoint regression analysis.ResultsFor men, in 2017, the median incidence of ILD was 7.22 (IQR 5.57–8.96) per 100 000 population. For women, in 2017, the median incidence of ILD was 4.34 (IQR 3.36–6.29) per 100 000 population. For men, in 2017, the median ASDR attributed to ILD was 2.04 (IQR 1.13–2.71) per 100 000 population. For women, the median ASDR in 2017 for ILD was 1.02 (0.68–1.37) per 100 000 population. There was an overall increase in ASDR during the observation period with a median change of +20.42% (IQR 5.44–31.40) for men and an increase of +15.44% (IQR −1.01–31.52) for women. Despite increases in mortality over the entire observation period, there were decreasing mortality trends in the majority of countries at the end of the observation period (75% for men and 86% for women).ConclusionOver the past two decades, there have been increases in the incidence and mortality of interstitial lung diseases in Europe. The most recent trends, however, demonstrate decreases in mortality from ILD in the majority of European countries for both men and women. These data support the ongoing improvements in the diagnosis and management of ILD.

Contemporary Concise Review 2022: Interstitial lung disease

“…There may be an identifiable cause or trigger, but in idiopathic pulmonary fibrosis (IPF) the aetiology is unknown. The incidence of IPF, along with prevalence and mortality, increased since the turn of the century in Australia, 1 a pattern which has been observed across all ILDs globally 2,3 . However, more recently trends of increased mortality have slowed or reversed partly due to considerable progress made in the field 1,2 .…”

“…The incidence of IPF, along with prevalence and mortality, increased since the turn of the century in Australia, 1 a pattern which has been observed across all ILDs globally. 2,3 However, more recently trends of increased mortality have slowed or reversed partly due to considerable progress made in the field. 1,2 The past year has seen continued advancements in identifying underlying pathomechanisms, improving diagnosis, managing comorbidities and developing treatments.…”

“…2,3 However, more recently trends of increased mortality have slowed or reversed partly due to considerable progress made in the field. 1,2 The past year has seen continued advancements in identifying underlying pathomechanisms, improving diagnosis, managing comorbidities and developing treatments.…”

Exploration of the unmet needs of patients diagnosed with idiopathic pulmonary fibrosis: a scoping review protocol

“…Interstitial lung disease (ILD) describes a large group of diseases that are identified by inflammation and fibrosis of the lung interstitium 1–3. A large subset of patients who are diagnosed with ILD have pulmonary fibrosis (PF).…”

An exploration of the unmet needs of patients diagnosed with Idiopathic Pulmonary Fibrosis (IPF): a scoping review protocol

“…Interstitial lung disease (ILD) describes a group of heterogeneous diseases that are identified by inflammation and fibrosis of the lung interstitium 4 5 . A large subset of patients who are diagnosed with ILD have pulmonary fibrosis (PF).…”